Month: December 2016

23 Dec 2016

Gates Foundation to Invest in HIV Prevention Device

“The Bill & Melinda Gates Foundation is investing as much as $140 million to support development of a tiny implantable drug pump it believes could help prevent people in sub-Saharan Africa and elsewhere from becoming infected with HIV, the virus that causes AIDS. The matchstick-size pump is being developed by Intarcia Therapeutics Inc., a closely held Boston biotechnology company. It can hold six or 12 months’ supply of medicine and is designed to deliver microdoses continuously to patients, ensuring they stay on the treatment.” as reported by the Wall Street Journal (http://www.wsj.com/)

“If we don’t find a way to prevent infection, we’re going to wind up with more people infected in that part of the world than we have now,” said Emilio Emini, director of the HIV program at the Gates Foundation. But “its real-world effectiveness is much lower than that because you have to take a pill” every day and getting healthy people to do so is difficult, Dr. Emini said. That is what makes Intarcia’s pump so attractive, he said. “You put it in and you forget it,” he said, likening it to long-acting forms of contraception. “You can immediately imagine how it could be applicable.”

Read the full article here : http://www.wsj.com/articles/gates-foundation-to-invest-up-to-140-million-in-hiv-prevention-device-1483023602

17 Dec 2016

TCD MENA: The family grows

What started one year ago as a dream, became a reality on 1 December 2016 when TCD MENA opened its doors in Heliopolis, Cairo as a full service CRO, serving the Middle-East and North-Africa region.

Being part of the TCD Group (www.tcd-global.com), our reach now extends from the Southern tip of the continent, to the North and the Middle-East. In the words of Dr. Hanaa Abdel-Maguid, managing director of TCD MENA: “Having been a sponsor of clinical trials for many years, I understand the needs of sponsors in a time when there are significant economic constraints globally. Part of our mission will be to convert these sponsor needs into innovative solutions that will compliment and support R&D objectives.”

The words of Eric Hoffer ring true: “In times of change, the learners shall inherit the earth, while the learned will find themselves perfectly equipped to manage a world that no longer exist.” As a learning organisation, the TCD Group will remain responsive to global trends and changing customer needs.

08 Dec 2016

Results from a TCD study : comparing generic Meropenem (Mercide®) with innovator brand (Meronem®)

Triclinium Clinical Development aided in the analysis and reporting of an in-practice study aimed at demonstrating therapeutic and bio-equivalence between a generic brand of meropenem and the innovator. The study demonstrated similar ex vivo efficacy and in vivo pharmacokinetics for the products under observation. Results suggest that the products are clinically interchangeable based on registration status, as well as bioassay results. A slightly higher observed generic meropenem AUC (approx. 4% higher) was observed, which is clinically acceptable due to a large therapeutic index.

For more in-depth reading, click here